CytRx Receives Letter From FDA
CytRx has received letter from the FDA regarding the arimoclomol phase IIb clinical trial. Under its guidelines, the FDA will have 30 days following CytRx’s planned protocol submission
Gilead Sciences has opened a new 182,000ft² research centre at its Foster City headquarters in California, US, for advancing medicines to treat challenging diseases.